Cancer

Autonomix Announces Reverse Stock Split

THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical…

1 year ago

Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib

European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the…

1 year ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative…

1 year ago

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute…

1 year ago

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20…

1 year ago

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,…

1 year ago

ProPhase Labs to Present at the 2024 ThinkEquity Conference

GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next…

1 year ago

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate…

1 year ago

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe…

1 year ago